“SSO2 Therapy will support clinicians in delivering the highest quality of care for their STEMI patients in Europe and other countries that accept CE Mark,” said Neil Johnston, president, ZOLL Circulation.
SSO2 Therapy delivers hyperbaric levels of oxygen directly to the damaged heart muscle immediately after successful revascularization via angioplasty and stenting of the blocked coronary artery. It is indicated for patients who suffer the most serious kind of heart attack, left anterior descending ST-elevation myocardial infarction (LAD STEMI)—also known as a “widowmaker” due to the high mortality rate—and are treated within six hours of symptom onset. SSO2 Therapy is the first and only U.S. Food and Drug Administration-approved device beyond percutaneous coronary intervention (PCI) to reduce muscle damage in heart attack patients.2
“I am very happy to know that ZOLL received CE Mark approval for the TherOx System,” said Antonio L. Bartorelli, M.D., interventional cardiology director at Centro Cardiologico Monzino, University of Milan. “We were among the first in Europe to observe the beneficial impact of SSO2 Therapy on left ventricular recovery after primary coronary intervention in patients with LAD ST-elevation myocardial infarction3 and we look forward to being able to use this effective treatment again in our patients.”
Historically, angioplasty and stenting have been the standard of care in treating heart attacks. Many patients do not achieve maximum clinical benefit and suffer from reduced heart function. More than 30 percent of severe heart attack patients develop heart failure,4 and of those, 50 percent will die within five years.4 SSO2 Therapy has been shown in prospective clinical trials to safely reduce infarct size in widowmaker heart attack patients. Decades of research on heart attack patients has demonstrated that infarct size reduction is correlated with reduced mortality and heart failure, and better left ventricular function.5
SSO2 Therapy was developed by Irvine, Calif.-based TherOx Inc., now part of ZOLL Medical Corporation. –MPO